Ask about this productRelated genes to: NONO antibody
- Gene:
- NONO NIH gene
- Name:
- non-POU domain containing octamer binding
- Previous symbol:
- -
- Synonyms:
- NRB54, NMT55, P54NRB, P54, PPP1R114
- Chromosome:
- Xq13.1
- Locus Type:
- gene with protein product
- Date approved:
- 1992-02-06
- Date modifiied:
- 2017-05-12
Related products to: NONO antibody
Related articles to: NONO antibody
- Paraspeckles are membrane-less subnuclear assemblies whose organization depends on the long isoform of nuclear paraspeckle assembly transcript 1 (NEAT1_2), which scaffolds paraspeckle proteins into a core-shell architecture. Disruption of the layered structure within paraspeckles occurs when paraspeckle components are depleted, potentially leading to functional impairment. Here, we describe a protocol for simultaneous visualization of NEAT1_2 middle region and transactive response DNA-binding protein 43 (TDP-43), which are enriched in paraspeckle core and shell, respectively, in U2OS human osteosarcoma cells. Sequential RNA-fluorescence in situ hybridization (RNA-FISH) and immunofluorescence, combined with high-resolution confocal microscopy, enable delineation of the paraspeckle core-shell structure. This method provides a robust approach for probing paraspeckle remodeling across diverse biological conditions. - Source: PubMed
Lee JoonwooGwon Youngdae - Pancreatic neuroendocrine neoplasms (panNENs) are rare endocrine malignancies with poorly defined risk factors, in contrast to the more common pancreatic ductal adenocarcinoma (PDAC), for which non-O ABO blood group is a well-established susceptibility marker. To determine whether ABO and related glycosylation markers associated with PDAC risk extends to panNENs, we conducted a case-control study of 1,059 pathologically confirmed panNEN cases from the ANONYMISED HOSPITAL Biospecimen Resource for Pancreas Research and 33,018 cancer-free controls from the ANONYMISED HOSPITAL Biobank. Using germline genotype data, we inferred ABO blood group, FUT2-defined secretor status, and FUT3-defined Lewis antigen phenotypes, and calculated odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression adjusted for age, sex, and ancestry principal components. ABO blood group was not associated with panNEN risk: compared with blood group O, the OR for non-O was 0.98 (95%CI: 0.87-1.11), with similarly null findings for blood groups A, B, and AB individually. Secretor status (OR=0.98, 95%CI: 0.84-1.14) and Lewis-positive phenotypes (OR=0.91, 95%CI: 0.75-1.13) were also not associated with risk, and no interactions were observed between blood group and secretor status or Lewis antigen phenotypes. Given our high statistical power to detect previously reported PDAC effect sizes for non-O blood group, these null findings are informative, indicating that the ABO-linked glycosylation, inflammatory, and host-microbe interaction pathways implicated in PDAC are unlikely to be major determinants of panNEN susceptibility. This study therefore sharpens the etiologic distinction between pancreatic exocrine and neuroendocrine cancers, redirecting panNEN research beyond PDAC paradigms toward alternative mechanisms of endocrine tumorigenesis. - Source: PubMed
Publication date: 2026/08/27
Antwi Samuel OCarlson Erin ERabe Kari GKoganti TejaBamlet William RHalfdanarson Thorvardur RMcWilliams Robert RWangensteen Kirk JOberg Ann L - : Blood transfusion is a key component of sickle cell disease (SCD) management, and ABO and Rh compatibility is essential to minimize transfusion-related complications. This study investigated factors associated with blood transfusion history and examined the relationships of ABO and Rh blood groups with clinical and laboratory markers of disease severity. : A cross-sectional study was conducted among 309 patients attending a hematology outpatient clinic in Saudi Arabia between October and December 2025. Clinical data were collected through patient interviews, and laboratory results were obtained from medical records. : Overall, 89.9% of patients had a history of blood transfusion. Older age, chronic disease, higher platelet count, MCV, MCH, and HbA2 levels were associated with blood transfusion history. In contrast, higher hemoglobin and HbF levels were associated with fewer transfusions. Patients with blood group O had lower odds of transfusion than those with non-O blood groups (OR = 0.340, 95% CI: 0.135-0.856; = 0.022). Hydroxyurea use was associated with lower LDH levels, while G6PD deficiency and higher MCV were independently associated with higher LDH levels. ABO and Rh blood groups were not associated with acute chest syndrome or LDH levels. : Blood transfusion history in SCD was associated with several clinical and hematological factors. These findings support further investigation of G6PD status and reinforce the known benefits of hydroxyurea. Further studies are needed to clarify the role of ABO and Rh blood groups in disease progression and transfusion practices. - Source: PubMed
Publication date: 2026/07/26
Alsalman MortadahAlSahlawi MuthanaAbid NaushadElzorkany KhaledAbdallah EmanAlQuraini AlaaAlkhalifa Hussain AbduljaleelShafey MarwaAlsalman Zaenb - ABO antigens are broadly expressed on endothelial and epithelial glycoproteins and modulate innate immune responses, complement activation, tissue immunogenicity, and endothelial-derived haemostatic factors. Their differential distribution across the specific diagnoses that lead to end-stage organ failure has been little explored in Latin American populations, where a high prevalence of group O provides a distinct genetic background to examine these associations. We report an exploratory analysis in national transplant waiting list of Ecuador. - Source: PubMed
Publication date: 2026/08/25
Velasteguí-Peñafiel ErickOrtiz FelipeCastillo María EstherYepez DoménicaCallatasig LeonardoVivanco-Arias CarlaVinueza-Flores AnghelyGarcia-Angulo Andrea - The abundance of a long non-coding RNA (lncRNA) is set by both its synthesis and its decay, yet for nuclear lncRNAs the contribution of decay - and whether decay rate is a determinant of function - has been little explored. I addressed this for NEAT1, the architectural scaffold of paraspeckles. By genome-wide half-life measurement (5'-bromouridine immunoprecipitation chase, BRIC), NEAT1 is a representative short-lived lncRNA at the median of the lncRNA half-life distribution (∼3.3 h), unlike the stable MALAT1. Using inhibitor-free decay measurement and bidirectional perturbation, I show that the core nuclear exosome (EXOSC5, EXOSC2), but not the 5'→3' exonuclease XRN2, the exosome-associated 3'→5' exonuclease EXOSC10, or the deadenylase PARN, sets the NEAT1 decay rate: exosome depletion lengthened the NEAT1 half-life (7.8 → 15.1 h) and raised its abundance; reciprocally, EXOSC5 over-expression shortened the NEAT1 half-life and EXOSC2 over-expression reduced its abundance. The resulting changes in NEAT1 abundance scaled the number and size of paraspeckles without increasing paraspeckle-protein mRNA levels, and changed the expression of candidate PSF/NONO target genes: across three orthogonal NEAT1 manipulations, increased NEAT1 abundance was associated with repression of RAP1A and TCF3 and activation of the NONO-regulated gene GJA1, without changing those mRNAs' own stabilities (under EXOSC5 depletion). These results, which complement the subsequently established exosome-adaptor mechanism of NEAT1 turnover by adding a direct decay-rate measurement and a functional read-out, identify RNA decay rate as a control point - a throttle - on lncRNA function, supported through bidirectional perturbation for NEAT1 in HeLa cells. - Source: PubMed
Publication date: 2026/08/21
Tani Hidenori